Skip to main content

Table 3 Comparison of the clinical features of patients with MS according to the presence or absence of HLA-DRB1*04:05

From: Latitude and HLA-DRB1*04:05 independently influence disease severity in Japanese multiple sclerosis: a cross-sectional study

DRB1

Total patients

Northern patients

Southern patients

04:05 (+) (n = 172)

04:05 (−) (n = 262)

p value

04:05 (+) (n = 92)

04:05 (−) (n = 155)

p value

04:05 (+) (n = 80)

04:05 (−) (n = 107)

p value

Number of males/females (ratio)

52/120 (1:2.3)

68/194 (1:2.9)

NS

27/65 (1:2.4)

35/120 (1:3.4)

NS

25/55 (1:2.2)

33/74 (1:2.2)

NS

Age (years)a

39 (31–49)

42 (34.2–51.5)

0.0259

41 (34–49.5)

42 (35–51)

NS

36 (28–49)

42 (34–52)

0.0334

Age at onset (years)a

26 (21–34.8)

30.2 (24–40)

0.0003

27 (21–34)

29 (24–37)

NS

25 (20–36.8)

33 (26–43)

0.0001

SPMS (%)

26/170 (15.3)

47/257 (18.3)

NS

19/92 (20.7)

34/153 (22.2)

NS

7/78 (9.0)

13/104 (12.5)

NS

Disease duration (years)a

9 (5.3–16)

9 (4–14)

NS

10 (6–17)

11 (5–17)

NS

7.5 (4–14.8)

5.5 (3–10.3)

0.0133

EDSSa

2.0 (1.0–3.5)

2.0 (1.0–3.5)

NS

2.0 (1.0–3.5)

2.0 (1.0–3.5)

NS

2.0 (1.0–3.0)

2.5 (1.5–4.0)

0.0263

MSSSa

2.10 (0.78–5.24)

3.17 (1.16–5.87)

0.0415

1.97 (0.56–5.63)

2.33 (0.88–4.94)

NS

2.28 (1.04–4.97)

4.32 (1.77–6.33)

0.0021

ARRa

0.40 (0.22–0.71)

0.43 (0.22–0.85)

NS

0.40 (0.25–0.71)

0.42 (0.22–0.75)

NS

0.37 (0.17–0.71)

0.48 (0.21–0.95)

NS

Barkhof criteria (%)

113/170 (66.5)

205/258 (79.5)

0.0026

69/92 (75.0)

129/155 (83.2)

NS

44/78 (56.4)

76/103 (73.8)

0.0143

Positive OB and/or increased IgG index (%)

58/129 (45.0)

135/200 (67.5)

<0.0001

41/69 (59.4)

89/108 (82.4)

0.0007

17/60 (28.3)

46/92 (50.0)

0.008

  1. The Mann–Whitney U test was used to compare continuous variables, and the chi-square test was used to compare categorical variables
  2. ARR annualized relapse rate, EDSS Kurtzke’s Expanded Disability Status Scale, MSSS Multiple Sclerosis Severity Score, NS not significant, OB oligoclonal IgG bands, SPMS secondary progressive multiple sclerosis
  3. aMedian (interquartile range)